Pulse Biosciences PLSE recently reported encouraging late-breaking data from the first-in-human feasibility study of its nPulse Cardiac Surgical System. The study data were unveiled at the 39th ...
COPENHAGEN - Pulse Biosciences, Inc. (NASDAQ:PLSE), a medical device company with a market capitalization of $1.3 billion and trading near its 52-week high of $25, announced positive initial results ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...
The introduction of cryoablation and pulsed field ablation (PFA) into electrophysiology (EP) labs has expanded the toolkit ...
A noninvasive MRI technique that measures volumetric changes in paraspinal muscles could transform how doctors assess nerve ...
News-Medical.Net on MSN
Advancements in organoids could transform treatment of spinal cord injury and peripheral nerve injury
A recent review published in Engineering explores the construction and potential applications of spinal cord and peripheral ...
Taste is one of our most vital senses, shaping appetite, nutrition, and quality of life. Yet taste buds are fragile, relying heavily on the nerves that connect them to the brain. When those nerves are ...
8don MSN
Study unveils mechanisms driving axonal accumulation of TDP-43 and associated nerve damage in ALS
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscle wasting and limb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback